SAB BIOTHERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
SAB BIOTHERAPEUTICS, INC. (SABS) had Debt Securities, Available-for-sale, Amortized Cost of $186.76 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $186.76M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $186.05M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $73.67M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $71.50M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $186.76M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $186.05M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $73.67M 10-K · filed 2026-03-09 |
| 2025-09-30 | $71.50M 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |